Will we ever see the approval of a Staphylococcus aureus vaccine?

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 10, 2011, Pages 845-846

  Patti, Joseph M ^a  

^a Inhibitex Inc   (United States)

Author keywords

active vaccination; antigens; immunogenicity; MRSA; S. aureus; vaccine

Indexed keywords

BACTERIAL VACCINE; PLACEBO; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; V710 VACCINE;

BACTERIAL CELL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NONHUMAN; PREDICTION; STAPHYLOCOCCUS INFECTION; VACCINATION; VACCINE PRODUCTION;

ANTIGENS, BACTERIAL; CATION TRANSPORT PROTEINS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; DRUG APPROVAL; HUMANS; INCIDENCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, ANIMAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; UNITED STATES; VACCINATION;

EID: 80053645199     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.99     Document Type: Editorial

References (8)

1. Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15), 1763-1771 (2007 (Pubitemid 47598444)
2. Deresinski S, Herrera V. Immunotherapies for Staphylococcus aureus: Current challenges and future prospects. Infect. Control Hosp. Epidemiol. 31(Suppl. 1), S45-S47 (2010
3. Harro JM, Peters BM, O'May GA et al. Vaccine development in Staphylococcus aureus: Taking the biofilm phenotype into consideration. FEMS Immunol. Med. Microbiol. 59, 306-323 (2010
4. Otto M. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin. Biol. Ther. 10(7), 1049-1059 (2010
5. Spellberg B, Daum R. A new view on development of a Staphylococcus aureus vaccine: Insights from mice and men. Hum. Vaccine. 6(10), 857-859 (2010
6. Fattom AS, Sarwar J, Ortiz, A, Naso R. Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64(5), 1659-1665 (1996
7. Etz H, Minh DB, Henics T et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc. Natl Acad. Sci. USA 10, 6573-6578 (2002 (Pubitemid 34526174)
8. Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macques and specific increased survival in a murine model of S. aureus sepsis. Infect. Immun. 74(4), 2215-2223 (2006).